ROBERT E. FALLON
Mr. Fallon is President and CEO of Phosplatin Therapeutics, a company he helped found. He is a highly respected manager with decades of global transactional and strategic leadership. He is former Chairman & CEO of a large publicly traded company, the Korea Exchange Bank, and prior to that he ran all of Asia-Pacific for J.P. Morgan Chase.
He holds a B.a. in mathematics from Ohio University, and an M.B.A. from Harvard Business School. Mr. Fallon also serves as Chairman of CIEE, the Council on International Educational Exchange, and is a member of the Council on Foreign Relations.
Matthew R. Price
Mr. Price is a co-founder of Phosplatin Therapeutics, and is responsible for strategy, finance and operations across the company's activities, which have expanded to thirteen countries since inception. He helped negotiate the original license for the company's PT-112 development program, and currently oversees the clinical and translational research & Development involving Phase I / II studies in solid tumors and hematological malignancies.He is also responsible for the company's sub-license collaboration with SciClone pharmaceuticals for greater China. In addition, he led the design and launch of the clinical trials collaboration jointly with pfizer and merck kgaa, darmstadt, germany.
He holds an A.b. from princeton university, graduating summa cum laude and phi beta kappa. he previously held research and managerial roles in the ngo and non-profit sectors. he made a career change, earning an m.b.a. with distinction from columbia business school, where he was a chazen society fellow in international business.
José Jimeno, M.D., Ph.d.
Dr. José Jimeno is a seasoned medical oncologist, who also holds a Ph.D. from the University of Barcelona, and leads the company's clinical development program. He has had a focus in drug development for over twenty years. Formerly VP of Clinical and scientific Development at Pharmamar, he was responsible for the integrated development of Yondelis®, which is approved in the U.s., the e.u., japan, and more than 60 other countries for the treatment of ovarian cancer and sarcoma.
His prior industry roles include work at Farmitalia Carlo Erba and US Biosciences, where he focused on novel compounds in the anthracycline and anti-metabolite therapeutic classes. Most recently, Dr. jimeno was co-founder and CEO of Pangaea Biotech, a cancer diagnostics company focused on personalized medicine, where he was involved in the development of the EGFR mutation diagnostic approved by the FDA for use in NSCLC cancer patients. Dr. Jimeno has published over 100 papers in peer review journals on cancer, and is a Guest Lecturer in immunology at the University of Zaragoza.
Tyler D. Ames, Ph.D.
Tyler is Vice President of Research at Phosplatin Therapeutics, and leads the company's translational research efforts globally across multiple institutions.
Dr. Ames received his B.S. with high distinction in Biology and Biotechnology from Worcester Polytechnic Institute, and earned his doctorate in Molecular, Cellular and Developmental Biology from Yale University, where he focused on nucleic acid biochemistry. Most recently he was a post-doctoral fellow at University of California Berkeley, focusing on commercial applications of yeast genetics.
Richard A. Wing, ph.d.
Dr. Wing serves the Phosplatin team as director of research and operations, responsible for supporting the management of the company's clinical and translational research and operations, along with its supply chain management. He was previously a post-doctoral fellow at rockefeller university, and most recently served as associate consultant at defined health, a boutique life sciences consultancy.
He earned a b.s. degree summa cum laude from vassar college, and his ph.d. in biochemistry from yale university.
Ms. Frances Bonham is Vice President of Finance and administration of phosplatin therapeutics, responsible for financial and administrative management, along with operational support. She has more than 25 years experience in the financial services industry, where she was a managing director at JP Morgan Chase, responsible for covering international clients. Most recently she worked in external affairs at the korea society in new york.
she earned her bachelors' degree from the university of michigan and her M.B.A. from the thunderbird graduate school of global management.
Joseph A. Rosamilia
Joseph Rosamilia leads business development efforts at Phosplatin. Over the course of his career Joh has established and managed business development groups for global Fortune 100 institutions in New York, London, Tokyo and Osaka where he expanded multi-product business lines across new geographic regions. He has structured and negotiated complicated deal structures as well as traditional financial assets accounting for several billion dollars of transactional experience.
After earning an M.B.A. from the Wharton school, Joh established a boutique advisory firm during which time he served the business development and finance needs at a number of early-stage private and OTC-traded public companies, as well as at a cross-border biotech investment fund. He also previosuly advised Phosplatin therapeutics on licensing and fund-raising overseas. He holds a B.A. degree from Colgate University where he studied organic and inorganic chemistry and majored in East Asian Studies.
Taylor B. Young
MS. YOung is director of strategic development at Phosplatin therapeutics, focusing on the company's development and commercialization strategies. Prior to joining the company, Taylor was a Senior Consultant in the Life Sciences group at Navigant Consulting, where she created and implemented innovative solutions to resolve commercial, clinical, and regulatory challenges across the drug development spectrum. Most recently, she was in Product Management at Willis Towers Watson, where she focused on product strategy and managed a team of software engineers.
She graduated from the joint-degree Roy & Diana Vagelos Program in Life Sciences and Management at the University of Pennsylvania, with a B.S. in Economics from the Wharton School and a concentration in Molecular Biology from the College of Arts and Sciences.
Ms. Malavé serves as Senior Associate for Research and Development at Phosplatin therapeutics, where she supports the clinical and non-clinical R&D and strategic initiatives of the company.
She is a graduate of stanford university, with a B.S. degree in bioengineering. at stanford, Celina worked in a synthetic biology lab, was a teaching assistant for the ethics in bioengineering class, and was the women in STEM coordinator at the stanford women's community center. She is concurrently pursuing a graduate degree at columbia university in the m.s. program in bioethics.
Pamela Y. Pak
Ms. Pak joins the Phosplatin Therapeutics team as Associate Director of Clinical Operations, responsible for managing the pharmaco-vigilance and clinical data associated with the company’s clinical development program. Prior to joining the company, Pamela was a clinical research coordinator at Mt. Sinai’s Icahn School of Medicine, where she was a co-author of an abstract focused on breast cancer mortality, presented at ASCO and published at the Journal of Clinical Oncology. Prior to that, she was a clinical data manager and research coordinator at Montefiore Medical Center (Albert Einstein College of Medicine) focusing on clinical trials in solid tumors and hematological oncology.
She earned her bachelor’s degree with distinguished independent work at Binghamton University.
Marie-therese hehenberger, m.s.
Ms. Hehenberger is Associate Director of Clinical Development at Phosplatin Therapeutics, where she is responsible for supporting the planning and management of the Company’s clinical trials and its clinical supply chain. She previously served as a Research Associate at the Company, where she engaged in fundamental research on drug candidates and supported ongoing pre-clinical programs. Most recently, Marie-Therese was a Clinical Research Associate at the Danish pharmaceutical company Novo Nordisk, where she focused on the management of clinical trials in diabetes. Prior to that, she developed stem cell-based biosensors as a Research Fellow at the Austrian Institute of Technology. She is a co-author of the publication titled Multi-layered, membrane-integrated microfluidics based on replica molding of a thiol-ene epoxy thermoset for organ-on-a-chip applications (Lab Chip 2015).
Marie earned her Master’s degree in Medical Biotechnology at the University of Natural Resources and Life Sciences in Vienna, Austria.
Lucas A. De Breed, Ph.D.
Dr. De Breed is an advisor at Phosplatin Therapeutics, supporting the team’s clinical strategy. He obtained his Ph.D. from University College London, completing his doctoral research in molecular oncology at the London Research Institute of Cancer Research UK, studying the epigenetic regulation of key tumor suppressor genes.
He established the East Coast office of Deallus Consulting in New York, where he conducted clinical and pipeline strategy engagements for biotechnology and pharmaceutical clients. Dr. De Breed holds an M.B.A. from the Stanford University Graduate School of Business.